Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Learn more about:
Related Clinical Trial
Bronchoscopic Laser Ablation of Peripheral Lung Tumors Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers Personalized PRRT of Neuroendocrine Tumors Clinical and Pathologic Studies in Neuroendocrine Tumors Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Active Surveillance in Early Lung Cancer Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Cabozantinib and Nivolumab for Carcinoid Tumors Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Endoscopic Treatment of Bronchial Carcinoid Tumors Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors A Study of Axitinib in Advanced Carcinoid Tumors A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Brief Title

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Official Title

A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Brief Summary

      This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in
      patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is
      to evaluate the rate of clinical benefit response to quarfloxin treatment including the
      reduction in secretory symptoms of flushing and/or diarrhea or the reduction quantifiable
      hormones or other biochemical tumor markers.

Study Phase

Phase 2

Study Type


Primary Outcome

Clinical benefit. Clinical benefit is defined as a reduction of secretory symptoms or reduction of quantifiable hormones or other biochemical tumor markers where concomitantly there is an absence of radiological evidence for tumor progression.

Secondary Outcome

 Evaluate response rate, duration of response and progression free survival per RECIST criteria and the plasma and whole blood levels of quarfloxin.


Neuroendocrine Tumors



Study Arms / Comparison Groups

Description:  Single arm study - open label.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 2008

Completion Date

March 2010

Primary Completion Date

March 2010

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically or cytologically confirmed low or intermediate grade neuroendocrine
             carcinoma including carcinoid and islet cell cancer. Patients with neuroendocrine
             tumors associated with MEN1 syndrome are eligible.

          -  Measureable disease by RECIST

          -  Unresectable or metastatic disease

          -  Secretory symptoms of diarrhea or flushing or both attributed to their carcinoid tumor
             and/or quantifiable hormones or other biochemical markers

          -  Males and females 18 years of age or older.

          -  Zero to two prior cytotoxic chemotherapy regimens.

          -  Patients may be receiving concomitant octreotide Sandostatin®

          -  Patients must have central IV access, or agree to the insertion of a central IV line.

          -  All previous cancer therapies, radiation, and surgery, must have been discontinued at
             least 21 days prior to the start of treatment.

          -  Acceptable liver function

          -  Acceptable renal function

          -  Acceptable hematologic status

          -  ECOG Performance Status ≤1.

          -  Anticipated survival of at least 6 months.

          -  Able to maintain a patient diary.

          -  For men and women of child-producing potential, use of effective contraceptive methods
             during the study and for one month after discontinuation of treatment.

          -  Ability to understand the requirements of the study, provide written informed consent
             and agree to abide by the study restrictions and return to the clinic for required

        Exclusion Criteria:

          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,
             adenocarcinoid, goblet cell carcinoid or small cell carcinoma.

          -  Pregnant or nursing women.

          -  Severe chronic obstructive pulmonary disease with hypoxemia or an uncorrectable
             pulmonary compromise.

          -  Seizures not controlled by anticonvulsant therapy.

          -  Participation in any investigational drug study within 28 days before quarfloxin
             administration or currently receiving investigational therapy.

          -  Patients with a second malignancy requiring active treatment.

          -  Active symptomatic bacterial, fungal, or viral infection including active HIV or viral

          -  Prior treatment with quarfloxin.

          -  Clinically significant bleeding event within the last 3 months, unrelated to trauma,
             or underlying condition that would be expected to result in a bleeding diathesis.

          -  Patients who have exhibited allergic reactions to a similar structural compound or

          -  Any illness or condition that in the opinion of the investigator may affect safety of
             treatment or evaluation of any of the study's endpoints.




18 Years - N/A

Accepts Healthy Volunteers



, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Study Sponsor

Cylene Pharmaceuticals

Study Sponsor

, , 

Verification Date

June 2011